



ORIGINAL ARTICLE

Skin Homeostasis is Impaired in Hidradenitis Suppurativa Lesions: A Comparative Study

Q1 A. Soto-Moreno^a, N. Delgado-Moya^a, M. Sánchez-Díaz^{a,c},
S. Arias-Santiago^{b,c,*}, A. Molina-Leyva^{b,c}

^a Dermatology Unit, Hospital Universitario Virgen de las Nieves Instituto de Investigación Biosanitaria IBS, Granada, Spain

^b School of Medicine, University of Granada, Granada, Spain

^c Hidradenitis Suppurativa Clinic, Dermatology Unit, Hospital Universitario Virgen de las Nieves, Granada, Spain

Received 14 March 2024; accepted 17 May 2024

KEYWORDS

Hidradenitis
suppurativa;
TEWL;
Homeostasis

Abstract

Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease whose impact on skin homeostasis has not been adequately studied at present. Knowledge about how skin function changes in these patients, and could be of interest not only to improve the topical management of the disease, but also as an objective measure of disease activity. The aim of this study was to compare skin homeostasis and the epidermal barrier function in lesional and healthy skin areas of patients with HS.

Methods: We conducted a cross-sectional study. Skin homeostasis and the epidermal barrier function of lesions were assessed in HS patients using validated tools. A healthy perilesional skin control was assigned to each lesion to compare skin homeostasis parameters.

Results: A total of 43 patients were included: 22 nodules, 10 abscesses and 25 draining tunnels were measured. The male-to-female ratio was 20:23, and the mean age, 35.95 years (SD, 14.82). Increased transepidermal water loss (TEWL) and erythema were found in nodules, abscesses and draining tunnel vs healthy skin. A direct association was observed between inflammatory nodules TEWL and IHS4 stage. In draining tunnels, a direct association was observed between TEWL and smoking. A trend of increasing TEWL values was observed as a function of Hurley stage.

Conclusion: HS lesions exhibit epidermal barrier dysfunction that depends on the severity of inflammatory activity. These results could be useful to develop objective classification systems for the severity and degree of involvement of HS or help in the development of vehicles for specific drugs, antiseptics and dressings for the management of this disease.

© 2024 Published by Elsevier España, S.L.U. on behalf of AEDV. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author.

E-mail address: salvadorarias@ugr.es (S. Arias-Santiago).

<https://doi.org/10.1016/j.ad.2024.05.027>

0001-7310/© 2024 Published by Elsevier España, S.L.U. on behalf of AEDV. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: A. Soto-Moreno, N. Delgado-Moya, M. Sánchez-Díaz et al., Skin Homeostasis is Impaired in Hidradenitis Suppurativa Lesions: A Comparative Study, ACTAS Dermo-Sifiliográficas, <https://doi.org/10.1016/j.ad.2024.05.027>

Alteración de la homeostasis cutánea en lesiones de hidradenitis supurativa, un estudio comparativo

Resumen

Introducción: La hidradenitis supurativa (HS) es una enfermedad crónica de la piel cuyo impacto sobre la homeostasis cutánea no ha sido adecuadamente estudiado en la actualidad. El conocimiento de cómo se modifica la función cutánea en estos pacientes podría ser de interés para mejorar el manejo tópico de la enfermedad y como medidas objetivas de la actividad de la misma. El objetivo de este estudio fue comparar la homeostasis cutánea y la función de barrera epidérmica en zonas de piel lesional y sana de pacientes con HS.

Métodos: Se realizó un estudio transversal. Se evaluaron la homeostasis cutánea y la función de barrera epidérmica en las lesiones de pacientes con HS mediante instrumentación validada. Se asignó un control de piel sana perilesional a cada lesión para comparar los parámetros de homeostasis cutánea.

Resultados: Se incluyeron 43 pacientes: se midieron 22 nódulos, 10 abscesos y 25 túneles de drenaje. La proporción hombre:mujer fue de 20:23, la edad media fue de 35,95 (desviación estándar [DE] 14,82) años. Se observó un aumento de la pérdida transepidérmica de agua (TEWL) y eritema en los nódulos, abscesos y túneles de drenaje en comparación con la piel sana. Se observó una asociación directa entre la TEWL de los nódulos inflamatorios y el estadio del *International Hidradenitis Suppurativa Severity Scoring System* (IHS4). En los túneles de drenaje, se observó una asociación directa entre la TEWL y el tabaquismo. Se halló una tendencia al aumento de los valores de TEWL en función del estadio de Hurley.

Conclusiones: Las lesiones de HS presentan disfunción de la barrera epidérmica dependiente de la gravedad de la actividad inflamatoria. Estos resultados podrían ser útiles para desarrollar sistemas de clasificación objetivos de la gravedad y el grado de afectación de la HS o para contribuir al desarrollo de vehículos para fármacos, antisépticos y apósitos específicos para el tratamiento de la enfermedad.

© 2024 Publicado por Elsevier España, S.L.U. a nombre de AEDV. Este es un artículo Open Access bajo la CC BY-NC-ND licencia (<http://creativecommons.org/licencias/by-nc-nd/4.0/>).

Introduction

Hidradenitis suppurativa (HS) is a chronic and progressive inflammatory disease characterized by the appearance of nodules, abscesses, and sinusoidal tracts in the inguinal, axillary, sub-mammary and anogenital areas^{1,2} which can impact the patient's quality of life significantly³ and be associated with several comorbidities.⁴ The pathogenesis of the disease is related to follicular hyperkeratosis and subsequent inflammation.

Some cytokines play a key role in the pathogenesis of the disease, including IL-1 β , IL-17 and TNF- α .⁵ Obesity, smoking, and hormonal disturbances are other predisposing factors that can impact the development and progression of the disease.^{6,7}

The management of these patients in all stages of severity usually includes topical treatment such as solutions, gels, ointments, creams, etc., or systemic treatment.^{8,9} Due to the anatomical areas where the lesions are located, it is a common thing to cover them with dressings, patches or gauzes. Knowing the homeostasis of the skin in skin regions touched by HS is the first step to establish recommendations or plan the design of topical treatment vehicles and dressings that respond to these patients' specific skin needs, since specific bandages for HS¹⁰ are not currently available.

The epidermal barrier is important to protect the human body from many external stressors and maintain skin

homeostasis.¹¹ Several methods have been described for assessing skin homeostasis and the epidermal barrier function, such as transepidermal water loss (TEWL), stratum corneum hydration (SCH), surface pH, temperature, elasticity, and erythema.¹²

The aim of this study was to compare skin lesions of HS and same healthy skin in terms of cutaneous homeostasis and epidermal barrier function in patients with HS to gain knowledge and understanding which could be used to assess specific ways to improve topical care of HS skin lesions.

Methods

Study design: We conducted a cross-sectional study to evaluate differences in homeostasis and the epidermal barrier function between HS skin lesions and perilesional healthy skin in patients with HS. Participants were recruited from the Dermatology Unit of Hospital Universitario Virgen de las Nieves, Granada, Spain.

Inclusion criteria: Patients older than 18 years of age with a clinical diagnosis of HS who had any kind of active lesion such as nodules, abscesses or draining tunnels with inflammation/supuration were included in the study.

Exclusion criteria: Patients with HS without active lesions, or those who did not give their prior written informed consent were excluded from the study.

114 **Study variables**

115 **Main variables of interest**

116 Homeostasis parameters and epidermal barrier function
117 variables were recorded using a multiprobe adapter. All
118 measurements were taken in the same room at a tempera-
119 ture of 23 ± 1 °C and an ambient air humidity of 45% (range,
120 40–50%). Recorded variables were:

- 121 a) Skin temperature (in °C, using Skin-Thermometer® ST
122 500)
- 123 b) TEWL (in $g\ m^2\ h^{-1}$ using Tewameter®™ 300
- 124 c) Erythema and melanin index (in arbitrary units (AU),
125 using Mexameter® MX 18)
- 126 d) SCH (in arbitrary units (AU), using Corneometer® CM825)
- 127 e) pH (using Skin-pH-Meter® 905)

128 These variables were measured in 2 areas of patients with
129 HS (in an inflammatory/suppurative nodule, abscess, or fis-
130 tula and in completely healthy skin located 5 cm away from
131 the edge of the lesion). A maximum of 1 lesion of each type
132 (nodule, abscess or fistula) was evaluated in each patient.

133 **Other variables of interest**

134 The severity of the disease was determined using Hurley
135 Stage,⁹ the refined Hurley classification (Hurley-R),¹¹ and
136 the International Hidradenitis Suppurativa Severity Score

System (IHS4 (referencia)), which were collected at that
time in the office.

Other socio-demographic and clinical data were
obtained, such as age, sex, age of onset, comorbidities,
family history, previous and current treatments and pre-
vious surgical procedures, disease phenotype and number
of affected regions. In addition, patients were questioned
about certain habits of interest, such as tobacco consump-
tion, type of deodorant routine, whether the lesion was
previously covered or not, products used for the hygiene of
the area and previous topical treatment of the lesion, etc.

Statistical analysis

Continuous variables were expressed as mean standard devi-
ations (SD). Qualitative variables were expressed as absolute
and relative frequency distributions. To compare continuous
variables, the Student *t*-test for independent samples or the
Student *t*-test for paired samples were used, as appropriate.
Pearson’s correlation coefficient was calculated to check for
possible correlations between continuous variables. Statisti-
cal significance was defined using a two-tailed *p* value < 0.05.
SPSS version 24.0 (SPSS Inc., Chicago, IL, United States) was
used.

Table 1 Overview of socio-demographic and clinical characteristics of the sample.

| Socio-demographic and clinical characteristics of the sample (n = 43) | | | |
|--|----------------|--|----------------|
| <i>Sex male:female</i> | 20:23 | <i>Current treatment</i> | |
| <i>Age (years)</i> | 35.95 (14.82) | Acitretin or other oral retinoids | 9.30% (4/43) |
| <i>Tobacco consumption</i> | 53.48% (23/43) | Antiandrogens | 2.32% (1/43) |
| <i>Hurley</i> | | | |
| I | 23.25% (10/43) | Oral antibiotics | 34.88% (15/43) |
| II | 62.79% (27/43) | Topical antibiotics/antiseptics | 6.97% (3/43) |
| III | 13.95% (6/43) | Anti IL-17A Biologic Drugs | 2.32% (1/43) |
| <i>Number of regions affected</i> | 2.74 (1.25) | Anti TNF Biologics | 39.53% (17/43) |
| <i>Hurley-patient refining</i> | | | |
| 1a | 13.95% (6/43) | Other | 4.65% (2/43) |
| 1b | 9.30% (4/43) | <i>Pretreatment</i> | |
| 2a | 23.25% (10/43) | Biological ± topical | 16.27% (7/43) |
| 2b | 30.23% (13/43) | Classic systemic ± topical | 76.74% (33/43) |
| 2c | 9.30% (4/43) | Classic systemic ± topical, biological ± topical | 2.32% (1/43) |
| 3a | 11.62% (5/43) | Topical only | 4.65% (2/43) |
| 3b | 2.32% (1/43) | <i>Deodorant</i> | |
| <i>International Hidradenitis Suppurativa Severity Score System (IHS4)</i> | 8.97 (7.64) | Does not employ | 30.23% (13/43) |
| <i>Duration (years)</i> | 15.74 (12.86) | <i>Roll-on</i> | 30.23% (13/43) |
| <i>Phenotype</i> | | <i>Spray</i> | 39.53% (17/43) |
| Follicular | 4.65% (2/43) | | |
| Inflammatory | 48.83% (21/43) | | |
| Mixed | 46.51% (20/43) | | |
| <i>N° of previous systemic treatments</i> | 2.37 (1.23) | | |
| <i>Previous surgeries (yes)</i> | 34.88% (15/43) | | |

Table 2 Characteristics of each type of HS skin lesions.

| Inflammatory nodules (n = 22) | | | |
|--|---------------|--|----------------|
| Area | | Hygiene products applied in the area | |
| Armpit | 31.81% (7/22) | Topical antiseptics (chlorhexidine, povidone iodine) | 18.18% (4/22) |
| Groin or upper thigh | 40.90% (9/22) | Homemade gel | 9.09% (2/22) |
| Perineum, buttocks, or gluteal fissure | 22.72% (5/22) | General purpose gel | 72.72% (16/22) |
| Abdominal folds | 4.54% (1/22) | Other | 0% (0/22) |
| Abscesses (n = 10) | | | |
| Area | | Hygiene products applied in the area | |
| Nape of the neck | 20.00% (2/10) | Topical antiseptics (chlorhexidine, povidone iodine) | 30.00% (3/10) |
| Groin or upper thigh | 10.00% (1/10) | General purpose shampoo | 10.00% (1/10) |
| Perineum, buttocks, or gluteal fissure | 40.00% (4/10) | General purpose gel | 60.00% (6/10) |
| Abdominal folds | 20.00% (2/10) | Degree of suppuration | |
| Other location | 10.00% (1/10) | Suppurative lesions | 70.00% (7/10) |
| Draining tunnels (n = 25) | | | |
| Area | | Hygiene products in the area | |
| Armpit | 52.0% (13/25) | Topical antiseptics (chlorhexidine, povidone iodine) | 8.0% (2/25) |
| Groin or upper thigh | 36.0% (9/25) | Homemade gel | 4.0% (1/25) |
| Breast or inframammary regions | 4.0% (1/25) | General purpose gel | 84.0% (21/25) |
| Perineum, buttocks, or gluteal fissure | 4.0% (1/25) | Degree of suppuration | |
| Other location | 4.0% (1/25) | Suppurative | 44.0% (11/25) |

Results

Characteristics of the sample

A total of 43 patients with HS (20 men and 23 women) were included. Mean age was 35.9 years (SD, 14.8). The most frequent Hurley stage was Stage II (62.7%, 27/43) and the mean value for IHS4 was 8.9 (SD, 7.6). Most common phenotypes were inflammatory (48.83%, 21/43), and mixed (46.51% – 20/43). Other sociodemographic and clinical characteristics are described in Table 1.

In terms of current treatment, most patients were on oral antibiotics or anti-TNF biologic drugs. Finally, deodorant was used in most patients in spray (39.53%, 17/43) or roll-on formats (30.23%, 13/43).

Cutaneous homeostasis parameters in lesional and healthy skin

Homeostasis was explored in different HS skin lesions, including inflammatory nodules, abscesses and draining tunnels:

Inflammatory nodules: The most common characteristics of inflammatory nodules included the most frequent location on the groin or upper thigh. For the most part, these lesions were not covered, and patients used general-purpose gel for personal hygiene (Table 2). The comparison of the parameters of the epidermal barrier function between inflammatory nodules and healthy perilesional skin can be seen in Table 3. Of note that TEWL and erythema were significantly higher ($p < 0.001$)

in the inflammatory nodule vs perilesional healthy skin. Temperature was higher in inflammatory nodules vs healthy skin, with trends toward significance ($p = 0.06$). Nonsignificant differences were found in SCH, pH, and melanin.

Abscesses: The most frequent location of abscesses was the perineum, buttocks or gluteal fissure. These lesions were mostly not covered, suppurated under pressure, and patients used general-purpose gel for cleaning these areas (Table 2). The comparison of skin homeostasis between abscesses and healthy perilesional skin can be seen in Table 3. TEWL and erythema were significantly higher ($p < 0.001$) in abscesses vs perilesional healthy skin. No statistically significant differences were found in SCH, pH, melanin, or temperature.

Suppurative draining tunnels: Draining tunnels were most frequently located at the armpit. Most of these lesions were not covered, did not have suppuration, and patients used general-purpose gel for personal hygiene (Table 2). The comparison of skin homeostasis between suppurative draining tunnels and healthy perilesional skin can be seen in Table 3. TEWL and erythema were significantly higher ($p < 0.001$), as well as temperature ($p = 0.003$) in suppurative draining tunnels vs perilesional healthy skin. No statistically significant differences were found in SCH, pH, or melanin.

Clinical and sociodemographic factors associated with TEWL

Clinical factors potentially related to changes in TEWL were explored. First, TEWL was higher in patients with higher Hurley stage for all skin lesions ($p < 0.01$). Moreover, a positive

275 levels of TEWL seem to correlate with higher Hurley stage in
276 all types of skin lesions. Therefore, TEWL could be a marker
277 of those patients with greatest disease severity. This objec-
278 tive parameter could help us identify the greatest severity
279 of HS and help us develop reproducible and accurate scales
280 and classification systems. On the other hand, studies with
281 larger sample sizes could provide findings with therapeutic
282 implications (for example, greater erythema could lead to
283 the use of topical corticosteroids and higher TEWL lead to
284 the use of topical astringents). Potential therapeutic impli-
285 cations or choice of hygiene products are difficult to predict,
286 given the absence of differences by type of treatment or
287 type of deodorant used in our study. However, these find-
288 ings are merely exploratory considering the small sample
289 size.

290 The lack of differences

291 This study has been limited by the difficulty of measuring
292 with probes, as they require a smooth surface to perform an
293 optimal measurement. Moreover, the presence of suppura-
294 tion could have altered some values such as SCH.

295 In conclusion, HS skin lesions show higher TEWL vs healthy
296 perilesional skin, which reflects a dysfunctional epidermal
297 barrier whose severity seems to be related to general dis-
298 ease severity. These results could be useful to develop an
299 objective classification of disease severity, or help develop
300 vehicles for drugs, antiseptics, and specific dressings for the
301 management of the disease.

302 Ethics

303 The present study was approved by the Research Ethics Com-
304 mittee of "Hospital Universitario Virgen de las Nieves" and
305 is in accordance with the Declaration of Helsinki.

306 Conflicts of interest

307 The authors have no conflicts of interest to declare.

308 References

309 1. Martorell A, García-Martínez FJ, Jiménez-Gallo D, Pascual JC,
310 Pereyra-Rodríguez J, Salgado L, et al. An update on hidradenitis
311 suppurativa (Part I): Epidemiology clinical aspects, and defini-
312 tion of disease severity. *Actas Dermosifiliogr.* 2015;106:703-15.
313 2. Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA,
314 Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical
315 Response): a novel clinical endpoint to evaluate therapeutic
316 outcomes in patients with hidradenitis suppurativa from the
317 placebo-controlled portion of a phase 2 adalimumab study. *J*
318 *Eur Acad Dermatol Venereol.* 2016;30:989-94.
319 3. Cuenca-Barrales C, Molina-Leyva A. Risk factors of sexual
320 dysfunction in patients with hidradenitis suppurativa: a cross-
321 sectional study. *Dermatology.* 2020;236:37-45.
322 4. Sánchez-Díaz M, Salvador-Rodríguez L, Montero-Vilchez T,
323 Martínez-López A, Arias-Santiago S, Molina-Leyva A. Cumula-
324 tive inflammation and HbA1c levels correlate with increased

intima-media thickness in patients with severe hidradenitis sup-
purativa. *J Clin Med.* 2021;10. Q3 324
325
326 5. Vekic DA, Frew J, Cains GD. Hidradenitis suppurativa, a review
327 of pathogenesis, associations and management. Part 1. *Aust J*
328 *Dermatol.* 2018;59:267-77.
329 6. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa:
330 epidemiology, clinical presentation, and pathogenesis. *J Am*
331 *Acad Dermatol.* 2020;82:1045-58.
332 7. Sánchez-Díaz M, Salvador-Rodríguez L, Cuenca-Barrales C,
333 Arias-Santiago S, Molina-Leyva A. Exploring the role of systemic
334 immune-inflammation index and neutrophil-lymphocyte ratio in
335 cardiovascular risk stratification for patients with hidradenitis
336 suppurativa: a cross-sectional study. *J Dermatol.* 2022. Q4 335
337 8. Alikhan A, Sayed C, Alavi A, Alhusayen R, Brassard A, Burkhart
338 C, et al. North American clinical management guidelines
339 for hidradenitis suppurativa: a publication from the United
340 States and Canadian Hidradenitis Suppurativa Foundations:
341 Part I: Diagnosis, evaluation, and the use of complementary
342 and procedural management. *J Am Acad Dermatol.* 2019;81:
343 76-90.
344 9. Sánchez-Díaz M, Díaz-Calvillo P, Rodríguez-Pozo JÁ, Arias-
345 Santiago S, Molina-Leyva A. Effectiveness and safety of acitretin
346 for the treatment of hidradenitis suppurativa, predictors of clinical
347 response: a cohort study. *Dermatology.* 2022;1-8. Q5 347
348 10. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D,
349 Juhász I, et al. European S1 guideline for the treatment of
350 hidradenitis suppurativa/acne inversa. *J Eur Acad Dermatol*
351 *Venereol.* 2015;29:619-44.
352 11. Clark RAF, Ghosh K, Tonnesen MG. Tissue engineering for cuta-
353 neous wounds. *J Invest Dermatol.* 2007;127:1018-29.
354 12. Romera-Vilchez M, Montero-Vilchez T, Herrero-Fernandez M,
355 Rodriguez-Pozo J-A, Jimenez-Galvez G, Morales-Garcia C, et al.
356 Impact of exposome factors on epidermal barrier function in
357 patients with obstructive sleep apnea syndrome. *Int J Environ*
358 *Res Public Health.* 2022;19.
359 13. Maroto-Morales D, Montero-Vilchez T, Arias-Santiago S. Study of
360 skin barrier function in psoriasis: the impact of emollients. *Life*
361 (Basel, Switzerland). 2021;11.
362 14. Montero-Vilchez T, Sanabria-de-la-Torre R, Sanchez-Diaz M,
363 Ureña-Paniego C, Molina-Leyva A, Arias-Santiago S. The impact
364 of dupilumab on skin barrier function: a systematic review. *J*
365 *Eur Acad Dermatol Venereol.* 2023;37:1284-92.
366 15. Stefanovic N, Irvine AD. Filaggrin and beyond: New insights
367 into the skin barrier in atopic dermatitis and allergic diseases,
368 from genetics to therapeutic perspectives. *Ann Allergy Asthma*
369 *Immunol.* 2023.
370 16. Montero-Vilchez T, Segura-Fernández-Nogueras M-V, Pérez-
371 Rodríguez I, Soler-Gongora M, Martínez-Lopez A, Fernández-
372 González A, et al. Skin barrier function in psoriasis and atopic
373 dermatitis: transepidermal water loss and temperature as use-
374 ful tools to assess disease severity. *J Clin Med.* 2021;10.
375 17. de Oliveira ASLE, Bloise G, Moltrasio C, Coelho A, Agrelli
376 A, Moura R, et al. Transcriptome meta-analysis confirms the
377 hidradenitis suppurativa pathogenic triad: upregulated
378 inflammation, altered epithelial organization, and dysregulated
379 metabolic signaling. *Biomolecules.* 2022;12.
380 18. Sivaprasad U, Kinker KG, Erickson MB, Lindsey M, Gibson AM,
381 Bass SA, et al. SERPINB3/B4 contributes to early inflammation
382 and barrier dysfunction in an experimental murine model of
383 atopic dermatitis. *J Invest Dermatol.* 2015;135:160-9.
384 19. Somogyi O, Dajnoki Z, Szabó L, Gáspár K, Hendrik Z, Zouboulis
385 CC, et al. New data on the features of skin barrier in hidradenitis
386 suppurativa. *Biomedicines.* 2023;11.